Research programme: carbon monoxide releasing molecules - Proterris

Drug Profile

Research programme: carbon monoxide releasing molecules - Proterris

Alternative Names: ALF 421; CORM-A1; CORMs - Proterris

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALFAMA
  • Developer Proterris
  • Class Aldehydes; Carbonates; Organometallic compounds; Small molecules
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammation; Liver failure; Multiple sclerosis; Non-alcoholic steatohepatitis; Rheumatoid arthritis

Most Recent Events

  • 16 May 2017 Proterris announces intention to submit IND to US FDA for Acute liver failure and non-alcoholic steatohepatitis in 2018 (Proterris pipeline, May 2017)
  • 16 May 2017 Proterris plans a phase I trial for Acute liver failure and non-alcoholic steatohepatitis (Proterris pipeline, May 2017)
  • 16 May 2017 Preclinical trials in Liver failure in Portugal before May 2017 (Proterris pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top